AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook

ANGIODYNAMICS INC

2023-Q1 EPS reported -$0.33 revenue$81,537,000

Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.
Med Tech net sales $22.8M (+29.6%), driven by Auryon (+50.0%) and thrombectomy (+31.8%); Med Device declined 1.1% to $58.7M.
Gross margin 51.9% down 20 bps; adjusted loss per share $0.06 vs $0.02 in prior year.
FY2023 guidance reaffirmed: net sales $342-348M, gross margin 52.5%-54.5%, adjusted EPS $0.01-$0.06.
New $75M credit facility with $30M term loan (drawn $25M); cash $24.6M; AlphaVac F18 full market release commenced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.